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We investigate a mechanism for the robust identification of the center of a developing biological
system. We assume the existence of two morphogen gradients, an activator emanating from the
anterior, and a co-repressor from the posterior. The co-repressor inhibits the action of the activator
in switching on target genes. We apply this system to Drosophila embryos, where we predict the
existence of a hitherto undetected posterior co-repressor. Using mathematical modelling, we show
that a symmetric activator-co-repressor model can quantitatively explain the precise mid-embryo
expression boundary of the hunchback gene, and the scaling of this pattern with embryo size.
PACS numbers: 87.18.La, 87.18.Bb, 05.40.-a
During embryonic development, cells have to differenti-
ate in a manner that is dictated by their positions within
the developing embryo. Turing conjectured that the posi-
tional information for differentiating cells is provided by
molecules called morphogens that self-organize into spa-
tial patterns [1]. Today a number of proteins have been
identified that act as morphogens. However, in contrast
to Turing’s original conjecture, morphogens are usually
produced at a localized source, after which they diffuse
into the surrounding tissue. Here, morphogens are also
degraded and a concentration gradient is thus formed.
The differentiating cells respond via patterns of gene ex-
pression that depend on the morphogen concentration [2].
However, the biochemical processes that give rise to the
morphogen gradient are prone to variations: the rates
of protein synthesis/degradation, for example, will vary
from embryo to embryo. Variation in these parameters
might modify the morphogen gradient and thereby in-
duce error in the positional information transmitted to
the differentiating cells. Nevertheless, cell differentiation
is often exceedingly precise [3]. How embryonic devel-
opment is robust against fluctuations in the underlying
biochemical processes is still poorly understood.
Recently, several mechanisms have been proposed to
explain robust embryonic development [4, 5, 6]. They
rely on the insensitivity of the morphogen gradient to
embryo-to-embryo variations in the morphogen synthe-
sis rates [4, 5, 6]. However, these mechanisms cannot
explain recent experimental observations on the Bicoid-
Hunchback system in the developing Drosophila em-
bryo [3]. bicoid (bcd) messenger RNA (mRNA) is de-
posited at the anterior pole of the embryo, where it
forms a localized source of Bcd protein. The Bcd pro-
tein diffuses away from the pole and is degraded, thereby
forming a concentration gradient (see Fig.1a). A sim-
ple ‘threshold’ model would postulate that downstream
genes such as hunchback (hb) are activated only when
the concentration of Bcd is above a certain threshold [2].
However, while the hb expression domain is highly pre-
cise, the Bcd morphogen gradient exhibits large embryo-
to-embryo variations [3, 7]. This rules out the above
mechanisms, which rely on the robust formation of the
morphogen gradient itself. Moreover, experiments reveal
that the Hb boundary, xHb, scales with the embryo length
(EL): xHb = 0.49 (± 0.01) EL [3]. Such scaling of expres-
sion domains cannot be explained by a single morphogen-
gradient model, in which positional information is only
emanating from one end. Indeed, this observation sug-
gests that the formation of the hb expression domain is
regulated by two or more morphogens, sourced at oppo-
site ends of the embryo. Earlier work of Wolpert [2] and
Meinhardt [8] already suggested that such models might
provide size regulation.
Motivated by recent experimental observations [9, 10],
which show that the activity of Bcd itself can be reduced
by interactions with other proteins called co-repressors,
we predict the existence of a second, as yet unidenti-
fied, morphogen that diffuses from a posterior-localized
mRNA source. The co-repressor binds to Bcd, thereby
inhibiting its ability to activate hb expression in the pos-
terior half of the embryo (see Fig. 1a). We show that such
a symmetric activator-co-repressor module can locate the
embryo center reliably. Our model thus generates ro-
bust patterns of gene expression that scale with size, a
result of potentially wide importance. Our calculations
reveal that the module is highly robust against correlated
embryo-to-embryo variations in the synthesis rates of the
anterior activator (Bcd) and posterior co-repressor. Fur-
thermore, variations in the synthesis rate of Bcd that are
uncorrelated with that of the co-repressor, are also fil-
tered far more than in a single-morphogen model. Iden-
tifying the proposed posterior morphogen may require a
large-scale search for maternal mRNA localized to the
posterior pole, which does not correspond to an already
characterized maternal gene.
Mathematical Model. The outline of our model is
2shown in Fig. 1: Bcd and co-repressor protein are in-
jected at rates JB , JR at opposite ends of the embryo,
where at each time instant the injection is concentrated
at a randomly chosen location xB(t), xR(t) between 5µm
and 30µm from the respective poles. The newly trans-
lated proteins diffuse away from the poles with diffusion
constant D, and are degraded at a rate µ. Bcd and the
co-repressor bind with rate ν to form a complex also with
diffusion constant D. We assume that the reverse reac-
tion occurs at a far slower rate, which we neglect. Only
active Bcd (unbound to co-repressor) binds to the hb con-
trol region on the DNA to activate its transcription. Ex-
periments suggest that this is a cooperative process [11],
which we model with a Hill function with a coefficient
of 3 [11]. However, the precise form of the activation
function is not very important: taking other functional
forms or changing the Hill coefficient to unity, for in-
stance, does not alter our results, as the concentration of
active Bcd is reduced to very low values at mid-embryo
due to the co-repressor (see also below). Hb also auto-
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FIG. 1: a: Sketch of Drosophila embryo showing localized
Bcd/co-repressor sources at opposite poles, and co-repressor-
Bcd binding. b-g: Positional information for Bcd and Hb
density profiles; data from 100 simulated embryos. Maxi-
mum densities normalized to unity. Mean density profile and
standard deviation for: b: Total Bcd (Bcd plus complex); c:
Unbound Bcd and co-repressor; d: Hb; in b)-d), 10 typical
individual density profiles are also shown. e: Distribution of
length scale λ describing exponential decay of total Bcd den-
sity profile. f: Distribution of positions xBcd and xHb where
each Bcd and Hb density profile crosses given threshold, 0.17
for total Bcd, 0.5 for Hb. g: Positions xBcd and xHb as func-
tion of embryo length (EL); Bcd: circles, Hb: squares. Green
straight line is xHb = 0.49 × EL.
activates its own synthesis via ‘synergistic’ interactions
with (active) Bcd [3, 12]. hb mRNA has diffusion con-
stant Dhb, and is spontaneously degraded with rate µhb.
Hb protein is manufactured at a rate proportional to the
mRNA concentration, has diffusion constant DHb and is
spontaneously degraded with rate µHb. These processes
give the following equations, where [B] is the unbound
Bcd density, [R] the co-repressor density, [C] the Bcd-
co-repressor complex density, [hb] the hb mRNA density
and [Hb] the density of Hb protein:
∂[B]
∂t
= D
∂2[B]
∂x2
− µ[B]− ν[B][R] + JBδ(x− xB(t))
∂[R]
∂t
= D
∂2[R]
∂x2
− µ[R]− ν[B][R] + JRδ(x− xR(t))
∂[C]
∂t
= D
∂2[C]
∂x2
− µ[C] + ν[B][R]
∂[hb]
∂t
= Dhb
∂2[hb]
∂x2
− µhb[hb] +
β[B]3(η[Hb] + γK)
K4 + [B]3(η[Hb] +K)
∂[Hb]
∂t
= DHb
∂2[Hb]
∂x2
− µHb[Hb] + α[hb] .
Here, we have used a simplified 1d model, where x mea-
sures the distance from the embryo’s anterior pole. Zero
flux boundary conditions were imposed at both embryo
ends. The wild-type parameters used were (see also [3]):
EL = 460µm, D = 10µm2s−1, Dhb = 0.5µm
2s−1, DHb =
1µm2s−1, JB = JR = 0.08s
−1, µ = 0.0007s−1, µhb =
0.004s−1, µHb = 0.006s
−1, ν = 3µms−1, α = 0.006s−1,
β = 0.004µm−1s−1, η = 1.0, γ = 0.01, K = 0.045µm−1.
We use the same diffusion constant/degradation rate for
the complex as for unbound Bcd; this ensures that the
total Bcd profile decays exponentially (as seen in experi-
ment [3]), but is not important for the basic center find-
ing properties of the model. Spatiotemporal fluctuations
of the components within a single embryo, which could
affect robustness [13], were also modelled but found to
be less important than embryo-to-embryo variability and
were therefore neglected. To simulate the embryo-to-
embryo variability, the embryo length fluctuated by 10%
[3]. Other parameters were varied by imposing a Gaus-
sian distribution about the above average values, using
the following standard deviation divided by the mean:
JB : 0.05, JR : 0.05, µ : 0.3, µhb : 0.3, µHb : 0.3, α : 0.3, β :
0.3,K : 0.3. The variations in the protein degradation
rates were assumed to be correlated, while we studied
both correlated and uncorrelated fluctuations in the Bcd
and co-repressor source strengths. Initially, the system
was empty of proteins and hb mRNA. The system reaches
a steady state after ∼ 1 hour, well before the window in
which the relevant experiments were performed [3, 7].
It is conceivable that an additional activator [14] dif-
fusing from the anterior competes with the co-repressor
for Bcd binding. This, however, does not significantly
change the results. Models in which the co-repressor
and/or the Bcd-co-repressor complex can also bind to
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FIG. 2: a: hb mRNA profiles in simulated Bcd(A52-56)
mutant (ν = 0.003µms−1). Inset: mean/standard devi-
ation for position of hb boundary as function of Bcd/co-
repressor binding rate ν (closed symbol denotes wild type). b:
Mean/standard deviation for Hb profile in mutant with mal-
functioning Hb protein. c: Mean/standard deviation for Hb
density profile in simulated staufen mutant (see text). Data
from 100 simulated embryos; maximum densities normalized
to unity; 10 typical individual profiles are also shown.
the DNA, but cannot then initiate hb transcription, again
produce very similar results. Schemes in which Bcd and
(co-)repressor only interact on the DNA, for instance by
mutually excluding each other’s DNA binding, provide
scaling, but are less robust to variations in their param-
eters than the model proposed here. Furthermore, we
have neglected the posterior morphogen nanos because
if nanos is removed, the key properties of accuracy and
scaling remain [3]. Lastly, while the co-repressor inacti-
vates Bcd at mid-embryo with respect to hb expression, it
does not impair Bcd’s capacity to activate other genes in
the embryo’s posterior, such as giant and knirps [15]. In-
deed, the Bcd domain that interacts with the co-repressor
plays an inhibitory role in hb expression, but a positive
role in knirps expression [16].
An alternative model has been suggested [17]; it as-
sumes that the mRNA-localization protein Staufen trans-
ports hb mRNA away from the poles via a counter-
intuitive mechanism relying on an increased diffusion rate
of hb mRNA upon binding to Staufen. However, scaling
is found over only 1-2 minutes rather than the required
hour or more. Moreover, it predicts a gradient of Staufen,
which is in contradiction with experiment [18]. Hence, as
proposed here, a different mechanism may be needed.
Results. Simulation results of the above model, with
uncorrelated fluctuations in the source stengths, are
shown in Fig. 1. The density of Bcd plus Bcd-co-repressor
complex decays exponentially away from the anterior
pole (Fig. 1b), in agreement with experiment [3]. The
total Bcd profile shows considerable embryo-to-embryo
variation, with the characteristic length scale λ =
√
D/µ
of the profile (Fig. 1e) and the position where the density
crosses a threshold (Fig. 1f), both showing large fluctu-
ations, similar to experiment [3, 7]. However, the pro-
files of the co-repressor/unbound Bcd fluctuate far less
from embryo to embryo (Fig 1c); the fact that they bind,
forces their unbound densities to very low values at mid-
embryo. The active Bcd is then able to precisely acti-
vate hb: the hb mRNA (data not shown) and Hb pro-
tein (Fig. 1d) densities both pass their half-maximum
values at xHb with little embryo-to-embryo variability,
xHb = 0.49 (±0.02)EL, see also Fig. 1f. The concentra-
tion profiles switch between their highest and lowest val-
ues over a length scale of about 0.1 EL. Both the average
position and variation of the Hb boundary, as well as its
steepness, are in agreement with experiment [3, 7]. Im-
portantly, the Hb boundary location scales with the em-
bryo size, unlike the Bcd profile [3, 7] (Fig. 1g). Further-
more, scaling is achieved even before the protein/mRNA
concentrations reach steady-state, adding additional ro-
bustness to the model. Finally, scaling can be obtained
even when the source strengths and λ are not the same
for Bcd and co-repressor (data not shown).
A critical test of our model comes from varying the
bcd gene dosage. When the dosage is halved (i.e. Bcd
injection rate halved), the Hb boundary moves to xHb =
0.39 (±0.02)EL. Simulations with twice and three times
normal dosage, but assuming only 50% efficiency for the
extra bcd genes as suggested by experiments [3, 10] (i.e.
1.5 and 2 times the wild type Bcd injection rate), move
the boundary to xHb = 0.56 (±0.025)EL and xHb =
0.60 (±0.03)EL, respectively. Both the results on the
mean and the variance agree with experiment [3]. In-
terestingly, the accuracy of hb expression is only weakly
affected by changes in the bcd gene dosage: the standard
deviation in xHb only increases by 50% when the Bcd in-
jection rate changes from 0.5 to 2 times the wild type Bcd
injection rate. More importantly, the average hb bound-
ary moves by less than predicted by a simple threshold
model [3]: the co-repressor gradient makes the boundary
positioning more robust to variations in the protein pro-
duction rates. Thus, the posterior morphogen not only
provides scaling, but it also plays an important role as a
4buffer against gene expression fluctuations.
Our model is also supported by several mutants. The
Bcd(A52-56) mutant inhibits the ability of Bcd to inter-
act with co-repressors [10]. We have modeled this by re-
ducing the Bcd/co-repressor binding by a factor of 1000.
Fig. 2a shows that this leads to a pronounced posterior
shift in the hb expression pattern, in agreement with ex-
periment [10]. We also predict that its precision will be
lost: the hb boundary fluctuates strongly as the poste-
rior co-repressor is no longer able to buffer against Bcd
fluctuations. Experiments have also been performed in
mutants that make detectable but malfunctioning Hb [3].
Normally Hb auto-activates its own synthesis [3, 12], and
our model includes this effect. If, however, we assume
that in this mutant Hb cannot stimulate its own synthe-
sis (corresponding to η = 0), then the Hb boundary shifts
anteriorly to xHb = 0.46 (±0.02)EL (Fig. 2b), while re-
taining its scaling properties. These results all accord
with experiment [3, 12]. Further support comes from
staufen mutants. Staufen plays a central role in polar lo-
calizing maternal mRNAs [18, 19]. In the stauHL/staur9
mutants, the precision of the Hb boundary is lost and
many of the Hb profiles are shifted anteriorly [3]. In
contrast, the Bcd profile is not altered in the stauHL
mutants [3]. Taken together, these observations strongly
suggest that in the stauHL/staur9 mutants, co-repressor
mRNA is no longer properly localized at the posterior
pole. We have studied this scenario by injecting a ran-
dom fraction of the co-repressor close to the posterior
(as described above), with the remainder randomly dis-
tributed throughout the embryo. The results are shown
in Fig. 2c: Hb boundary precision is lost, and many pro-
files shift towards the anterior (xHb = 0.43 (±0.05)EL),
in agreement with experiment [3].
To isolate which embryo-to-embryo variations are most
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FIG. 3: Magnitude of variations in position of Hb bound-
ary as a function of relative magnitude (standard deviation
σ/mean value) of embryo-to-embryo variations in model pa-
rameters. Both uncorrelated and correlated variations in the
injection rates JB , JR are shown (see text). When varying the
fluctuations of one parameter, other parameters were fixed to
their wild type values, indicated by closed symbols.
important, we studied the magnitude of the fluctuations
in the Hb boundary position as a function of the embryo-
to-embryo variability of various parameters. Correlated
variations that affect Bcd and the co-repressor similarly
have little effect, due to the symmetry of the activator-
co-repressor geometry (see Fig. 3). If, for instance, both
Bcd and co-repressor are degraded by the same pathway,
then the embryo-to-embryo variations in their degrada-
tion rates are correlated and thus filtered out (see Fig. 3).
Furthermore, it is conceivable that not only degrada-
tion, but also synthesis of Bcd and co-repressor exhibit
correlated embryo-to-embryo fluctuations, because they
share, for instance, the same components of the tran-
scription/translation apparatus. These correlated vari-
ations of the Bcd/co-repressor injection rates are again
filtered (see Fig. 3). However, Bcd/co-repressor synthesis
may also exhibit some uncorrelated variation. As we dis-
cussed above, our symmetric activator-co-repressor sys-
tem buffers fluctuations far more than would be possible
in a single morphogen system. Nevertheless, these uncor-
related fluctuations are not completely filtered out and, if
large enough, can adversely affect the accurate position-
ing of the hb expression domain (see Fig. 3). Our model
therefore predicts that Bcd synthesis must be tightly con-
trolled, at least relative to that of the co-repressor.
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